Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHA Regimen for Induced Therapy in Adults de Novo Acute Myeloid Leukemia (Non-M3)
NCT05906914Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2022
- Primary completion
- Apr 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine, homoharringtonine, cytarabine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Oct 2022; status: completed.
02
Drugs
cladribinehomoharringtoninecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05906914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05906914.